INTRODUCTION
============

Structural plasticity in neurons can be defined as a series of measurable changes in the morphologically defined components of the neuron, i.e., numbers, size, and composition of soma, dendrites, axons, and synapses, occurring over time and in response to changes in the cell environment. Structural plasticity can also be seen as one aspect of neuroadaptation, a general process present in neurons of specific neural circuits when responding to repeated physiologic stimuli, pathologic agents, or effective doses of pharmacologic substance, including addictive drugs ([@B24]). These stimuli act by engaging molecular mechanisms that are critical for cell growth and survival, their impact on the cell morphology being defined by the stimulus intensity and by genetic and epigenetic predisposing factors that constitute the neuroadaptive potential of the cells.

Since 1990s neuroadaptation and plasticity have been recognized to be relevant in addiction disorders characterized by chronic misuse of neuroactive substances ([@B32]; [@B49]; [@B16]; [@B17]). In mammals, pharmacologic agents characterized by their addictive properties, for example psychostimulants (e.g., cocaine, amphetamines), opioids (e.g., heroin and morphine), nicotine, cannabinoids, and alcohol, were found to engage dopaminergic neurons of the mesocorticolimbic contingent located in the ventral tegmental area (VTA) ([@B32]; [@B16]; [@B34]; [@B6]). These neurons produce dopamine (DA) as principal neurotransmitter, project to cortical and limbic brain structures and are involved in regulation of motivation, reward, motor response selection, mood, and arousal. While a large body of experimental findings supports the role for dopaminergic neurotransmission in mediating the addictive properties of these drugs ([@B32]; [@B16]; [@B34]; [@B28]; [@B6]), less research was dedicated to the structural changes occurring during exposure to addictive drugs or following their withdrawal. The initial interest on structural plasticity was focused on glutamatergic and GABAergic neurons of nucleus accumbens and prefrontal cortex, i.e., on neurons located in terminal fields of the mesencephalic dopaminergic system ([@B56], [@B57]; [@B59]) rather than on their presynaptic side. In dopaminergic neurons structural plasticity was indirectly inferred on the basis of changes in the expression of "marker" proteins though to be involved in structural changes, such as axonal neurofilaments ([@B49]), a phenomenon only later confirmed using morphological techniques ([@B66]). In fact, by definition, structural plasticity requires morphologic evidence. Dopaminergic neurons are generally identified by immunocytochemistry or immunofluorescence with selective antibodies that recognize tyrosine hydroxylase (TH) or dopamine transporter (DAT; [@B30]). When applied to the *post-mortem* study in mammalian brains, TH immunocytochemistry allows reliable estimate of soma size and neuron counts in substantia nigra (SN, also identified as A9) and VTA (also identified as A10). Conversely, a proper analysis of the dendrite length and branching is not possible, due to the complex overlapping of the dendritic arborizations of adjacent dopaminergic neurons. Visualization of dendrites and dendritic spines of a single neuron requires different approaches, such as the classical Golgi-Cox staining ([@B27]) associated with immunohistochemistry ([@B68]) intracellular injection with Lucifer Yellow via micropipettes ([@B66]) or diolistic gene gun delivery of fluorescent dyes ([@B64]). Dopaminergic neurons can be studied *in vitro* using primary cell cultures from the ventral mesencephalon of rodent embryos or newborns ([@B65]; [@B9]). The *in vitro* approach allows the simultaneous evaluation of soma size, dendritic arborization, dendritic spines, neurochemistry, and intracellular molecular signaling due to their sparse distribution in the culture dish and their standardized control conditions ([@B9], [@B7]).

In this article we summarize the evidence of structural plasticity occurring in mesencephalic dopaminergic neurons following exposure to addictive drugs, focusing on soma, and dendritic arborization rather than synapses and addressing the key molecular intracellular signaling involved.

STRUCTURAL PLASTICITY IN DOPAMINERGIC NEURONS AS CELLULAR NEUROADAPTATION: OPPOSITE EFFECTS OF OPIOIDS AND PSYCHOSTIMULANTS
===========================================================================================================================

Structural plasticity includes hyperplastic and hypoplastic phenomena, i.e., the increase or decrease of number and size of morphologically defined components of the neuron. In the brain reward circuit, drugs of addiction produce both hyperplastic and hypoplastic phenomena, the former generally associated to psychostimulants, the latter to the use of opioids (for review see [@B60], [@B59]). Since chronic exposure to both opioids and psychostimulants produces behavioral sensitization, compulsive drug taking, and relapse after extinction, at the time of their initial discovery these changes appeared somewhat contradictory, casting some doubts about the relevance of structural plasticity in addictive behavior. Recent findings regarding the role of withdrawal state ([@B69]; [@B46]), region-specific changes of synaptic spines ([@B59]) and differential regulation of endogenous neurotrophins, in particular brain derived neurotropic factors (BDNF) ([@B60]; [@B31]), have been advocated as key factors in disentangling this paradox; some possible explanations will be reviewed later in this article.

Chronic exposures to opioids reduce soma size and dendrites of the dopaminergic neurons located in the VTA of adult rodents without reducing the number of neurons ([@B66]; [@B70]; [@B58]). Opioid-induced hypotrophic effects on soma were observed following either passive dosing or self-administration of heroin or morphine and persist for several weeks during withdrawal. Functionally, chronic exposure to opioids is known to increase VTA neural firing while reduction is observed during withdrawal ([@B14]; [@B31]).

Reduced soma size and neural firing were also observed during withdrawal from cannabinoids in rodents ([@B13]; [@B69]). These effects are partially determined by endogenous opioids since acute morphine attenuates the behavioral cannabinoid withdrawal syndrome in mice ([@B39]). Interestingly, chronic exposure to cannabinoids *per se* does not produce change of soma sizes of VTA dopaminergic neurons. Lack of change in the soma size was also recently showed in rats trained to chronically self-administer cocaine, nicotine, and alcohol when sacrificed in presence of drugs ([@B46]). These data do not rule out the possibility of changes during withdrawal or crash after drug taking "binges," both conditions associated to a functional hypodopaminergic state ([@B76]; [@B47]; [@B79]); so far structural effects were not studied.

Cocaine and amphetamine exposures *in vivo* increase dendrite arborization and spines in VTA ([@B48]; [@B61]). *In vitro* studies on primary cultures of mesencephalic neurons from mouse embryos corroborate this evidence. Dose-dependent increases of soma size, maximal dendrite length, and number of primary dendrites were observed ([@B9], [@B7]). Interestingly, also nicotine was shown to increase structural plasticity of dopaminergic neurons *in vitro*, effect blocked by mecamylamine and dihydro-β-erythroidine but not methyllycaconitine, suggesting the involvement of α4β2 nicotinic receptor (nAChR; ([@B8]). These nicotinic hetero-receptors expressed in dopaminergic neurons control DA release and are critical for the reinforcing effects of nicotine *in vivo* ([@B52]). Consistently, dopaminergic neurons from the mesencephalon of α4 nAChR-subunit knock out (KO) mice did not show nicotine-induced plasticity ([@B8]).

Prenatal exposure to either cocaine or nicotine during the last gestational phase (E17-21) was associated with significant increase of soma size of dopaminergic neurons in newborns and young mice ([@B7], [@B8]). Prenatal exposures to cocaine and amphetamines produce long-term changes in the behavior and neurochemistry of the mesencephalic dopaminergic system of offspring assessed as adults ([@B10]; [@B41]), suggesting a possible association between dopaminergic structural plasticity and liability to develop addiction.

CRITICAL ROLE OF THE BDNF-TrkB SIGNALING IN DETERMINING STRUCTURAL PLASTICITY OF DOPAMINERGIC NEURONS EXPOSED TO ADDICTIVE DRUGS
================================================================================================================================

Neurotrophic factors that bind to the tropomyosin-related kinase B (TrkB) receptor were shown to be of importance in the development of the central nervous system (CNS) and in shaping neuronal morphology of dopamine neurons and other brain circuits (for a review see [@B51]). In particular, BDNF-TrkB signaling has been extensively studied as critical mediator of the structural changes produced by addictive drugs ([@B60]; [@B31]). Mesencephalic dopaminergic neurons significantly express BDNF since prenatal time ([@B2]). Still present in adult life, BDNF expression can be transiently increased by psychostimulants in VTA dopaminergic neurons ([@B20]). These increases consolidate and persist over time during abstinence ([@B54]) and during extinction of drug self-administration and in craving incubation paradigms ([@B21]). Infusion of BDNF in VTA induces long-lasting potentiation of cocaine seeking during abstinence ([@B42]), while BDNF immunoneutralization attenuates the cocaine addictive behavioral effects ([@B20]). To our knowledge, direct evidence of structural changes in dopaminergic neurons during withdrawal, abstinence and incubation with psychostimulants is lacking in literature. However, in consideration of the well-known BDNF neurotrophic properties on dendrites and soma size, it is possible to speculate that some structural plasticity could occur. Interestingly, GDNF, another neurotrophic factor, increases in VTA during cocaine withdrawal and mediates incubation of cocaine craving ([@B43]), further supporting possible structural effects.

Almost opposite effects were observed with opioids: morphine reduces BDNF expression in VTA neurons; low BDNF levels were associated with reduced soma size, and local infusion with BDNF normalizes soma size ([@B66]; [@B60]). Recent studies using conditional KO mice and optogenetic technology showed that morphine-induced low levels of BDNF in the VTA are associated to hypersensitization of VTA dopaminergic neurons to morphine, whose administration increases firing and DA release, producing conditioned place preference ([@B31]). Conversely, acute withdrawal and abstinence are associated with increased BDNF expression and TrkB-mediated plasticity changes that are essentials for negative reinforcing effects of morphine withdrawal ([@B72]). Interestingly, the opioid effects on DA release are indirect, mediated by GABAergic inhibitory neurons under glutamatergic control ([@B4]; [@B73]; [@B26]), suggesting a role also for these neurotransmitters.

The main intracellular pathways activated by BDNF-TrkB signaling are the MEK-ERK, the PI3K-Akt-mTORC1, the PLCy-DAG-PKC/Ca^2+^, and NFkB pathways, all involved in cell survival and growth ([@B35]; [@B60]). These pathways are not only activated by BDNF but also by G-protein coupled receptors (e.g., [@B19]). Recent evidence indicates that cocaine and nicotine activate both MEK-ERK and Akt-mTORC1 pathways in primary cultures of dopaminergic neurons ([@B7], [@B8]). Phosphorylation in these two pathways was found critical for structural plasticity since pretreatments with selective inhibitors for ERK, PI3K, and mTORC1 block the increase of soma size and dendritic arborization produced by psychostimolants and nicotine ([@B8]). Conversely, morphine exposure was associated with reduction in Akt levels and phosphorylation, attenuating mTOR-dependent phosphorylation ([@B58]; [@B46]). The central role of the PI3K-Akt-mTOR pathway in determining soma size of mesencephalic dopaminergic neurons is exemplified by the phosphatase and tensin homolog (PTEN) KO mice. PTEN is a negative regulator of PI3K whose null mutation leads to a constitutive preferential state of activation of Akt-mTORC1 pathway; the result is a massive increase in soma size of dopaminergic neurons already visible in newborns, that persists in adult mice ([@B15]). Other mechanisms affecting dendrite and soma size include the modulation of Ca^2+^ levels and the cAMP production, the latter not operated by BDNF. A large body of evidence indicates that Ca^2+^-dependent AMPA and NMDA glutamate receptors regulate dendrite growth in pyramidal neurons and interneurons ([@B23]). In dopaminergic neurons NMDA-dependent axonal growth was described as related to CaMKII phosphorylation ([@B63]), while preliminary *in vitro* data indicate a critical role for AMPA receptors. In GABAergic neurons located in the VTA, chronic activation of the cAMP-PKA-CREB was associated with reduced firing and soma size in dopaminergic neurons during morphine withdrawal ([@B4]; [@B31]), suggesting an indirect involvement in structural plasticity.

Interestingly, structural changes of soma size and dendritic arborization of dopaminergic neurons are not specific of addictive drugs. In a recent article a reduction of soma size in the VTA was observed in male rats after single and repeated mating episodes ([@B53]). Naloxone treatment reversed soma size reduction and attenuated the longer-term expression of experience-induced facilitation of sexual behavior without affecting its rewarding properties. In another study, an increase of the number, size, and dendritic spines of mesencephalic dopaminergic neurons was associated to exercise and intense motor behavior in rats exposed to moderate dose of dopaminergic neurotoxins ([@B55]), supporting a role for neurotrophic BDNF-TrkB signaling in behaviorally induced structural plasticity.

DOPAMINE AS NEUROTROPHIC FACTOR: ROLE OF D3 RECEPTOR SIGNALING IN STRUCTURAL PLASTICITY OF DOPAMINERGIC NEURONS
===============================================================================================================

In addition to its role as a neurotransmitter, DA can act as neurotrophic factor. When released in the extracellular space, DA binds to postsynaptic receptors, producing structural plasticity: for example DA increases TrkB phosphorylation via D1 receptor ([@B25]). DA also binds to presynaptic D3, D2~S~, and D5 receptors located on dopaminergic neurons ([@B78]). Functional studies in mutant mice indicate that D2 and D3 receptors are complementary in regulating phasic and tonic dopamine release from dopaminergic nerve terminals in caudate and nucleus accumbens ([@B37]; [@B44]). The intracellular pathways activated by the presynaptic DA receptors and related to structural plasticity are only partially understood, being the majority of studies performed in non-dopaminergic cells. Converging findings indicated a primary role for D3 receptors in dopaminergic structural plasticity via phosphorylation of MEK-ERK1/2 and PI3K-Akt-mTORC1 pathways ([@B11]; [@B3]; [@B7], [@B8]). Conversely, D2s receptors inhibit MEK-ERK1/2 pathway and are negatively coupled with adenylate-cyclase ([@B71]). PLCy activation and β-arrestin non-canonical pathways were described for the D2L splice variant present on postsynaptic neurons ([@B12]). Finally, less data are available on D5 receptor, whose role has been related to functional plasticity ([@B62]; [@B1]).

Direct evidence linking D3 receptors and structural plasticity was recently obtained in primary cultures of dopaminergic neurons from mouse embryos. Repeated exposure with low doses of D3-preferential agonists, such as quinpirole or 7OH-DPAT, increased soma size and the number and length of primary dendrites ([@B9]). These effects were also produced by drugs of addiction such as cocaine, amphetamine, nicotine, and ketamine, all known to increase extracellular levels of DA in the VTA. Pretreatments with DA D3 selective antagonist SB277011-A and the non-selective D2/D3 antagonist sulpiride resulted in a blockade of dendrite outgrowth and soma size ([@B9], [@B7]). No structural plasticity was observed when treatments with psychostimulants or nicotine were performed in cell cultures from the mesencephalon of D3 KO mice ([@B9], [@B7], [@B8]). When nicotine was repeatedly administered to pregnant D3 KO mice during the last gestational phase, no effect was observed on the soma size of VTA neurons of newborns. Recent evidence suggests that D3 receptors work in concert with BDNF-TrkB signaling. *In vivo* experiment showed that D3 receptor expression depends on the levels of BDNF ([@B22]) and that cocaine exposure increases the synthesis of both BDNF and D3 receptors ([@B36]), while morphine increases the expression of D3 receptors only ([@B67]), marking a difference between the two addictive drugs (**Figure [1](#F1){ref-type="fig"}**).

![**Schematic representation of relevant intracellular pathways of BDNF and dopamine dependent structural plasticity in dopaminergic neurons.** TrkB, tropomyosin-related kinase B; Src, proto-oncogene tyrosine protein kinase; MEK, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase; D3R, dopamine D3 receptor; Giβγ, G protein; PI3K, phosphatidylinositol 3-kinase; Akt, serine threonine kinase or protein kinase B; mTORC1, mammalian target of rapamycin complex 1; p70S6K, p70 ribosomal S6 protein kinase; PD98059, MEK inhibitor; LY294002, PI3K inhibitor; rapamycin, mTORC1 inhibitor; SB277011A, selective D3R inhibitor.](fphar-05-00259-g001){#F1}

HUMAN EVIDENCE OF ADDICTIVE DRUG INDUCED STRUCTURAL PLASTICITY
==============================================================

No direct human evidence of structural plasticity induced by addictive drugs in dopaminergic neurons is currently available. *Post-mortem* studies in cocaine users revealed a 16% reduction of melanized dopaminergic neurons with no reported change of soma size ([@B40]), while a reduction of TH levels in dopaminergic terminals of the striatum was found in heroin addicts ([@B29]).

*In vivo* neuroimaging studies, which lack cellular resolution, showed reduced 6-FDOPA uptake in the dopaminergic terminals of the striatum of cocaine addicts during 10--30 days of abstinence ([@B77]). Interestingly, another marker of dopaminergic terminals in striatum, i.e., DAT levels, was found reduced in methamphetamine addicts ([@B5]) and in tobacco and marijuana smokers ([@B38]). Extracellular DA release estimated using the 11C-raclopride displacement techniques indicated a lower DA tone in ventral striatum of cocaine ([@B45]) and marijuana users ([@B74]), the latter correlated with enhanced stress reactivity and irritability, confirming a hypodopaminergic state. Structural MRI showed a volumetric increase in the left nucleus accumbens in marijuana users ([@B18]), enlarged striatum in methamphetamine users ([@B5]) and reduction in nucleus accumbens, anterior cingulated and orbitofrontal cortex in children exposed *in utero* to opioids ([@B75]), all findings in line with preclinical observations.

CONCLUSION AND FUTURE RESEARCH
==============================

Addictive drugs induce structural plasticity in dopaminergic neurons. While a complete picture of structural changes associated to the different stages of the addiction cycle and its translational value in human is still lacking, differences among the main addictive drugs in producing either hypotrophic or hypertrophic response stand out, driven by the respective down or up regulations of BDNF and extracellular dopamine levels. These effects can be more conspicuous during neural development, as shown in offspring following *in utero* exposure or *in vitro* using embryo-derived cell cultures. Overall, structural changes appear to be related to some differences in targeting of reward and stress circuits that work in parallel to control motivation ([@B33]; [@B24]). These long term structural changes can be seen as substrates of "memory" traces ([@B50]) that would eventually constitute a liability for drug taking relapse.
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